Peptide education
KPV
Lysine-proline-valine
KPV is a three-amino-acid fragment, Lys-Pro-Val, from the tail end of the hormone alpha-MSH. It keeps the parent hormone's anti-inflammatory signaling while being too short to touch the pigmentation pathway, which is exactly why researchers find it interesting. The published case is one of the better preclinical stories on this site: colonic cells actually take it up through the PepT1 transporter, it calms inflammatory signaling, and it works in mouse colitis models. The case against the market version is simpler: no human has been dosed with KPV in any trial these sources found, and the delivery papers exist precisely because getting it where it needs to go is still an unsolved engineering problem.
KPV has a real mechanism and real mouse colitis data, and not one human trial. Every capsule, cream, and vial on the market is an extrapolation from animals.
Overview
Quick answer
KPV is separate from the GHK-Cu + KPV blend. The blend is a gray-market pairing of two separate ingredients, so GHK-Cu skin data or blend vendor claims cannot show what standalone KPV does.
What is it?
KPV is Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH. In the literature it is an anti-inflammatory and antimicrobial peptide fragment studied in cells and mice, not an approved drug and not a clinically tested one.
What do people use or discuss it for?
Gut inflammation above all: ulcerative colitis, Crohn's, "leaky gut," general digestive complaints. Skin irritation, wound healing, and immune calming come second, often through creams or GHK-Cu blends. The published research supports the first theme in mice and says nothing tested about the rest.
What route details do the studies and market claims give?
The only real route science is preclinical: PepT1-mediated uptake into colonic cells, and hyaluronic-acid nanoparticles engineered to carry KPV to inflamed mouse intestine. Community protocols describe 250 to 500 mcg subcutaneous once or twice daily, or 500 mcg to 1 mg daily in capsules, for 4 to 8 weeks. Those numbers are convention; no human dose exists in the cited sources.
What does the evidence actually support?
That KPV deserves a human trial, and that nobody has run one. PepT1 uptake work explains how it enters gut-lining and immune cells, mouse IBD models show an anti-inflammatory effect, a colitis-associated cancer model extends the theme, and the nanoparticle paper shows researchers still have to build special vehicles to deliver it orally. A ClinicalTrials.gov search turned up no direct human KPV trial, and FDA flags the missing exposure data.
Reported practice
Commonly reported protocol
Injectable community protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
The main listed KPV sources involve PepT1-mediated uptake, inflammatory signaling, and mouse inflammatory-bowel-disease models. These studies explain why gut-inflammation claims exist, without making KPV a human IBD treatment.
KPV has oral-delivery literature in preclinical colitis models, including hyaluronic-acid-functionalized nanoparticles. That is formulation research, not a human oral protocol.
Skin, wound, and barrier claims are limited to antimicrobial or inflammation biology and FDA materials that flag missing human data. The listed KPV sources stop short of a topical wound-care or skin-treatment regimen.
A trial search did not turn up a direct human KPV efficacy, exposure, or safety study in these sources. FDA materials also emphasize missing human exposure data, so human-efficacy conclusions are premature.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| KPV treats ulcerative colitis, Crohn's disease, or gut inflammation. | A direct human KPV efficacy trial was not found. The ClinicalTrials.gov source is a search result, not a trial reporting clinical outcomes. | The gut rationale is real but preclinical. Listed studies discuss PepT1-mediated KPV uptake, inflammatory signaling, mouse IBD models, colitis-associated cancer models, and oral nanoparticle delivery in ulcerative-colitis models. | Online and clinic discussion commonly turns KPV into gut-health and inflammation language. The broader research materials do not give a verified human route, dose, or follow-up pattern for those claims. | Reasonable to describe as preclinical gut-inflammation biology. Turning that into a human IBD treatment or gut-healing protocol would need human exposure and outcome data. |
| KPV helps with skin inflammation, barrier repair, or wound healing. | No cited human KPV skin or wound trial supports a treatment claim. The cited material does not provide a topical dose, frequency, duration, finished product, or clinical endpoint for skin or wound use. | KPV is part of alpha-MSH-derived anti-inflammatory and antimicrobial peptide research, which is why skin and wound claims show up around it. The listed KPV sources, however, are still laboratory, animal, regulatory, or adjacent-mechanism evidence. | Skin and wound language appears around peptide-market products and blend-style marketing, especially when KPV is paired with GHK-Cu. Those discussions use the blend's positioning rather than showing KPV-alone human wound efficacy. | Skin and wound claims can be mentioned as market and mechanism themes, but no demonstrated KPV skin or wound protocol was found. |
| KPV has antimicrobial effects. | The listed antimicrobial source is laboratory context. It supports a mechanism discussion, not a human infection-treatment claim. | Alpha-MSH peptide work supports antimicrobial discussion, including KPV-related sequence context. That helps explain why infection and skin claims show up, but it does not define a human route or clinical target. | Product and wellness discussion can turn antimicrobial wording into broad claims about microbes, skin, wounds, or gut balance. The laboratory source does not supply a human target, route, or outcome. | Discussable as laboratory antimicrobial biology, not as an infection-treatment claim. |
| Oral KPV is a ready-to-use gut protocol. | No human oral KPV regimen is listed. The route-specific evidence available here is preclinical delivery research. | PepT1 uptake and nanoparticle delivery studies make oral delivery worth studying. They do not give a finished-product capsule amount, schedule, cycle length, safety monitoring plan, or finished product. | Broader market material includes oral and compounded-product interest, but exact use details remain anecdotal unless human evidence verifies them. | Oral delivery is still a research problem here. The human evidence does not provide a ready-to-use protocol. |
| KPV is safe because it is short and derived from alpha-MSH. | Endogenous or fragment-style naming cannot answer whether an oral, topical, or injectable KPV product is tolerated in people. FDA compounding-risk materials are relevant because no human exposure or safety data for KPV drug products are presented here. | Short sequence length does not remove route, dose, immune, formulation, degradation, sterility, or impurity concerns. Preclinical anti-inflammatory effects still leave human tolerability untested. | Vendor and clinic pages often compress KPV into a simple inflammation peptide. Identity, concentration, sterility, route-specific exposure, and long-term safety still have to be checked before treating oral, topical, injectable, or blend products as interchangeable. | The safety picture is thin because human exposure data, route-specific tolerability, and finished-product quality evidence are missing. |
Bottom line
Main takeaway
KPV is an anti-inflammatory fragment with convincing mouse data for gut inflammation and no human trials at all. Everything sold for gut or skin is untested in people.
Sort claims by evidence type: PepT1 papers are mechanism, mouse colitis papers are animal models, the nanoparticle paper is formulation research, FDA material is a missing-data warning, and vendor pages are marketing. None of them is a human result.
The source set is PepT1/colitis 2008, murine IBD 2008, oral nanoparticle delivery 2017, colitis-associated cancer 2016, the alpha-MSH antimicrobial paper, a trial-registry search, and FDA compounding material. Preclinical throughout.
The honest summary is short: no human route, dose, tolerability profile, or product standard exists in the cited literature. FDA's compounding-risk file exists precisely because the human data do not.
Identity
What it is
KPV is the tripeptide Lys-Pro-Val, the last three amino acids of alpha-MSH. Cutting the hormone down to this fragment keeps the anti-inflammatory signaling relevant to gut models while losing the melanocortin pigmentation effects, which is why it gets discussed as its own compound rather than as a melanotan relative.
The mechanistic hook is unusually concrete for a peptide this small. The PepT1 di/tripeptide transporter carries KPV into colonic epithelial and immune cells, giving oral and nanoparticle formulations a plausible route to inflamed tissue. Mouse colitis models, a colitis-associated cancer model, and alpha-MSH antimicrobial lab work fill out the preclinical picture.
What does not exist is the human half. No direct efficacy, exposure, or safety trial turned up in the cited registry search. Meanwhile the name appears on research vials, compounded capsules, creams, and GHK-Cu blends, and the blend marketing in particular borrows GHK-Cu's skin reputation to make KPV look clinically established. It is not.
How people talk about it online
Online, KPV is gut talk: colitis, Crohn's, "leaky gut," food reactivity, with skin and wound claims layered on top. Protocol blogs converge on 250 to 500 mcg injected once or twice daily, or 500 mcg to 1 mg daily in capsules, usually for 4 to 8 weeks. Since no human dose exists anywhere in the literature, those numbers are copied convention, nothing more.
The oral capsule market leans on a misreading of the delivery science. The nanoparticle papers get cited as if they validate oral KPV generally; what they actually show is that researchers needed a custom hyaluronic-acid carrier to get KPV to inflamed mouse intestine. A plain capsule is not that system.
GHK-Cu blends are the other distorting force. Pairing KPV with a copper peptide lets marketing combine two rationale stories into skin and repair claims, while contributing zero KPV-alone human data.
Use context
Routes, doses, and cycle patterns
KPV route details here are mostly preclinical. Oral delivery is tied to PepT1 and nanoparticle-model work; oral products, topicals, injectables, and blends are market patterns rather than human regimen sources.
Human studies and product labels
PepT1-mediated intestinal uptake and colitis biology
- Purpose
- Intestinal inflammation mechanism and mouse-colitis effects
- Context
- Cell and mouse preclinical study
- Route
- Intestinal uptake / oral-delivery-relevant biology
- Amount
- Laboratory and animal exposure only
- Frequency
- Laboratory and animal exposure only
- Duration
- Study-specific preclinical exposure
This is one of the key reasons KPV is discussed for gut inflammation. It supports mechanism and animal-model interpretation; it is not a human oral regimen.
Murine inflammatory-bowel-disease models
- Purpose
- Anti-inflammatory activity in animal IBD models
- Context
- Murine preclinical study
- Route
- Study-specific animal exposure
- Amount
- Animal-model exposure only
- Frequency
- Animal-model exposure only
- Duration
- Study-specific animal-model duration
The animal findings are relevant to the gut-inflammation rationale. They do not show whether KPV helps Crohn's disease, ulcerative colitis, IBS, or general gut discomfort in people.
Oral nanoparticle delivery in ulcerative-colitis models
- Purpose
- Targeted KPV delivery to inflamed intestinal tissue in preclinical ulcerative-colitis models
- Context
- Preclinical delivery-system study
- Route
- Oral targeted nanoparticle delivery in models
- Amount
- Preclinical delivery-system exposure only
- Frequency
- Preclinical delivery-system exposure only
- Duration
- Study-specific preclinical exposure
The route detail matters because it is often flattened into "oral KPV." This was a designed delivery system in models, not a standard capsule protocol.
PepT1 and colitis-associated cancer model
- Purpose
- Colitis-associated cancer biology and potential therapeutic benefit in a mouse model
- Context
- Murine preclinical study
- Route
- Study-specific animal exposure
- Amount
- Animal-model exposure only
- Frequency
- Animal-model exposure only
- Duration
- Study-specific model duration
This adds another PepT1-centered mouse model. It is not cancer-prevention or cancer-treatment evidence in people.
Alpha-MSH antimicrobial peptide context
- Purpose
- Laboratory antimicrobial activity discussion
- Context
- Laboratory antimicrobial peptide study
- Route
- Laboratory exposure
- Amount
- Laboratory exposure only
- Frequency
- Laboratory exposure only
- Duration
- Laboratory study setting
This explains antimicrobial interest in KPV-related alpha-MSH peptide sequences. It does not supply a clinical infection, skin, gut, or wound regimen.
Real-world discussion
Injectable community protocols
- Purpose
- Gut and inflammation discussion
- Context
- Clinics, forums, and protocol blogs
- Route
- Subcutaneous injection
- Amount
- Most community sources put it at 250 to 500 mcg per injection, once or twice daily
- Frequency
- Once or twice daily in most descriptions
- Duration
- Most often 4 to 8 week runs
KPV is an alpha-MSH fragment with preclinical anti-inflammatory data; human dosing is unstudied, so these ranges are community convention only. Reported as context, not a recommendation.
Oral and topical community use
- Purpose
- Gut-focused and skin-focused discussion
- Context
- Capsule and cream products, clinics
- Route
- Oral capsules or topical creams
- Amount
- Oral products are commonly marketed around 500 mcg to 1 mg per day
- Frequency
- Once or twice daily
- Duration
- Most often 4 to 8 week runs
Oral KPV is marketed for gut claims on the same logic as oral BPC-157, with the same absence of human outcome data.
What varies
- KPV's gut rationale comes from cell and mouse studies; nanoparticle work shows that reaching intestinal tissue is still an engineering problem. Human efficacy and tolerability remain untested.
- Route matters: preclinical oral-delivery systems cannot be used as evidence for standard oral capsules, topical products, injections, or blends.
- Amount matters: the listed KPV sources do not provide a human dose range, frequency, or cycle length.
- Product form matters: KPV in a research vial, compounded product, oral delivery system, topical product, or GHK-Cu blend may differ in identity, concentration, purity, sterility, stability, and degradation risk.
- Claim matters: gut inflammation, IBD, skin inflammation, wound healing, antimicrobial effects, and immune calming do not all rest on the same evidence.
Human data
Human evidence
There is no human evidence to summarize. The cited trial-registry search found no direct human KPV efficacy, exposure, or safety study, and FDA compounding materials emphasize the same gap. The strongest sources are preclinical: PepT1-mediated uptake, murine colitis models, an engineered oral nanoparticle system, a colitis-associated cancer model, and laboratory antimicrobial work. Those explain why the compound is worth studying and why it is marketed. They cannot say whether it helps any person with any condition.
Evidence maturity
KPV is a mechanism-rich fragment whose human evidence has not caught up with its colitis-model reputation.
Colitis models, antimicrobial studies, and PepT1-mediated delivery research.
No controlled human outcome trials for gut or inflammation claims.
Injectable and oral products in clinic and gray-market channels.
PCAC voted on July 23, 2026 to recommend KPV bulk substances for the 503A Bulks List (8-6, one abstention). The vote is advisory only; FDA rulemaking follows, so compounding status is unchanged today.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Human KPV trial search | No direct human KPV efficacy population found | ClinicalTrials.gov search and literature-review context | No approved KPV drug product found in the listed material | The cited KPV sources do not include a direct human efficacy, exposure, or safety trial. | A search result is not a clinical outcome, and trial registries can change over time. | Weak; no direct human trial listed |
| PepT1-mediated intestinal inflammation work | Cell and mouse colitis models | Preclinical mechanistic and animal study | Laboratory KPV exposure, not a finished human product | Reported KPV uptake and anti-inflammatory effects relevant to intestinal inflammation biology. | Does not show human efficacy, human dose, oral product equivalence, or clinical safety. | Preclinical |
| Murine inflammatory-bowel-disease KPV work | Mouse IBD models | Animal preclinical study | Laboratory KPV exposure | Supports anti-inflammatory potential in murine inflammatory-bowel-disease models. | Mouse IBD findings do not establish benefit in Crohn's disease, ulcerative colitis, IBS, or broader human gut symptoms. | Preclinical |
| Oral nanoparticle KPV delivery | Ulcerative-colitis model systems | Preclinical delivery-system study | Hyaluronic-acid-functionalized nanoparticle delivery, not a standard oral KPV product | Reported efficient alleviation of ulcerative-colitis model findings with targeted KPV delivery. | Delivery-system data cannot be generalized to capsules, drops, injections, or topical products without human pharmacology and product data. | Preclinical |
| KPV in colitis-associated cancer model | Mouse colitis-associated cancer model | Animal preclinical study | Laboratory KPV exposure | Supports PepT1-centered discussion in a murine colitis-associated cancer model. | Not human cancer treatment or prevention evidence. | Preclinical |
| Alpha-MSH antimicrobial peptide context | Laboratory antimicrobial context | In vitro / laboratory antimicrobial peptide work | Peptide-sequence biology, not a clinical infection product | Supports antimicrobial context for alpha-MSH peptide fragments including KPV-related sequence discussion. | Laboratory antimicrobial findings do not define human infection, skin, wound, or gut treatment use. | Preclinical |
Cautions
Safety and unknowns
- Human exposure and tolerability data were not found for KPV in the listed material. That leaves efficacy, route-specific dosing, and adverse-event expectations unresolved.
- Route-specific risk is unclear. Oral targeted delivery in preclinical models does not answer topical, injectable, standard oral, compounded, or blend-product safety.
- Long-term safety, pregnancy and lactation risk, immune effects, hypersensitivity, infection-related use, wound-use safety, and interaction risks are not characterized by the listed KPV sources.
- Skin and wound claims are especially easy to overstate because antimicrobial and anti-inflammatory biology alone does not provide a topical wound-care product, dosing schedule, sterile manufacturing standard, or clinical outcome.
- FDA compounding-risk and PCAC context raises product-quality and safety questions, especially when a product is compounded, gray-market, or presented as a research material.
- Product identity, purity, concentration, sterility, endotoxin, degradation, stability, delivery vehicle, and lot-to-lot consistency matter more than the short peptide name alone.
Product quality
A vial label is only a starting point
KPV products may be presented as research vials, compounded preparations, oral products, topical products, or blend ingredients. A gut capsule claim, a wound-care topical, and a sterile injectable raise different exposure and quality questions.
Preclinical oral-delivery studies used designed systems, so standard oral KPV products remain uncharacterized for tissue reach and human exposure.
A public purity number or COA leaves open sterile quality, concentration accuracy, endotoxin control, degradation after reconstitution, delivery-system performance, and whether the tested lot represents the product being used.
Identity
The material has to be the intended Lys-Pro-Val peptide rather than a mislabeled or degraded product.
Route and formulation
A nanoparticle delivery system, topical preparation, injection, and oral capsule can produce different exposure and risk.
Sterility and endotoxin
Injection or wound-facing claims also need sterile-route controls, endotoxin limits, and finished-product handling evidence.
Concentration and dose math
Without verified concentration and product-specific instructions, amount statements can be wrong before any benefit claim is evaluated.
Stability and degradation
Short peptides can still degrade or adsorb depending on storage, solvent, container, temperature, and time after reconstitution.
Blend compatibility
KPV mixed with GHK-Cu or other peptides needs its own compatibility and stability evidence. Separate component biology cannot show whether a finished blend remains intact or works in people.
Mechanism
How it is proposed to work
KPV is studied as a small alpha-MSH-derived peptide fragment that may reduce inflammatory signaling in preclinical systems. In gut models, the key idea is that intestinal transport and local uptake can bring KPV to cells involved in inflammation, where it may dampen signaling pathways that drive inflammatory responses.
The listed gut literature emphasizes PepT1-mediated uptake, intestinal epithelial and immune-cell context, and reduced inflammatory signaling in preclinical colitis models.
The oral nanoparticle paper matters because it treats delivery as a problem to solve. It does not mean a standard oral KPV product reaches the same target tissue in humans.
Antimicrobial alpha-MSH peptide work helps explain why KPV is discussed around microbes, skin, wounds, and barrier biology, but laboratory antimicrobial activity does not tell whether an infection improves in a person.
The GHK-Cu + KPV blend hypothesis pairs KPV's inflammation rationale with GHK-Cu's skin and matrix rationale. For KPV alone, that pairing explains market positioning, not human efficacy.
KPV is the C-terminal tripeptide of alpha-MSH. It retains anti-inflammatory signaling relevant to gut models while being too short to activate the pigmentation pathway associated with the full hormone, which is why it is discussed separately from the melanotan family.
A distinctive mechanistic detail is PepT1-mediated uptake: the di/tripeptide transporter carries KPV into colonic epithelial and immune cells, which is the rationale behind oral and nanoparticle formulations in colitis models.
FAQ
Common questions
What is KPV supposed to do?
KPV is a three-amino-acid fragment of alpha-MSH studied mainly for anti-inflammatory effects in gut and skin models. The evidence is cell and animal work — colitis models, antimicrobial studies, and delivery-system research — not controlled human outcome trials.
What do community protocols look like?
Commonly 250 to 500 mcg by subcutaneous injection once or twice daily, or 500 mcg to 1 mg daily in oral gut-focused products, usually for 4 to 8 weeks. These are community conventions without human dosing studies behind them.
Is KPV related to melanotan?
Yes, by family: KPV is the C-terminal tripeptide of alpha-MSH, the same hormone family as the melanotan peptides. It does not share their tanning pharmacology — its discussion is anti-inflammatory, not pigmentation.
Is KPV being reviewed by regulators?
The FDA Pharmacy Compounding Advisory Committee voted on July 23, 2026 to recommend KPV bulk substances for the 503A Bulks List, 8-6 with one abstention. The recommendation is non-binding: KPV is not FDA-approved, and compounding status does not change until formal FDA rulemaking, which historically takes a year or more.
Details
Technical details
Sources
References
- 1.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
- 2.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 3.
PubMed. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation 2008.
PMID:18061177 Accessed 2026-06-08.
KPV intestinal inflammation source; preclinical/mechanistic lane.
- 4.
PubMed. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease 2008.
PMID:18092346 Accessed 2026-06-08.
Murine IBD evidence; not a direct human efficacy source.
- 5.
PMID:28143741 Accessed 2026-06-08.
Nanoparticle delivery source in ulcerative colitis models; not clinical protocol evidence.
- 6.
PMID:27458604 Accessed 2026-06-08.
Murine colitis-associated cancer model; mechanism/preclinical lane only.
- 7.
PubMed. Antimicrobial effects of alpha-MSH peptides 2000.
PMID:10670585 Accessed 2026-06-08.
Alpha-MSH peptide antimicrobial context including KPV-related sequence discussion.
- 8.
ClinicalTrials.gov. ClinicalTrials.gov search for KPV 2026.
Accessed 2026-06-08.
No matching KPV clinical trial records were used from the current registry search.